Pitcairn’s Abiomed Inc ABMD Stock Holding History

Pitcairn’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,044	Closed	-$272K	–	558
2019 Q2	$272K	Buy	+1,044	New	+$277K	0.03%	427

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Pitcairn's ABMD Position: Q3 2019 in Review

Pitcairn sold out of Abiomed Inc (ABMD) in Q3 2019, closing a stake of 1,044 shares — an estimated $272K sold.

Pitcairn first reported a position in ABMD in Q2 2019 and held it in 1 quarter. The position peaked at $272K in Q2 2019. 443 funds tracked by Wall St. Rank hold ABMD as of Q3 2019.

Pitcairn reported no remaining Abiomed Inc position as of Q3 2019 after selling out during the quarter.
Pitcairn sold 1,044 Abiomed Inc shares in Q3 2019, an estimated $272K.
Pitcairn first reported a position in Abiomed Inc in Q2 2019 and held it in 1 quarter.
Pitcairn's Abiomed Inc position peaked at $272K in Q2 2019.
443 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2019.

Based on Pitcairn's 13F filing for Q3 2019, filed 12 Nov 2019.